Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma

European Journal of Internal Medicine

Volumn 17, Issue 6, 2006, Pages 412-416

  Alexandrakis, Michael G ^a   Pappa, Constantina A ^a   Miyakis, Spiros ^b   Sfiridaki, Aikaterini ^c   Kafousi, Maria ^d   Alegakis, Athanassios ^d   Stathopoulos, Efstathios N ^d  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c Venizelion General Hospital   (Greece)

^d UNIVERSITY OF CRETE   (Greece)

Author keywords

Angiogenesis; Interleukin 17; Microvessel density; Multiple myeloma; Tumor necrosis factor ; Vascular endothelial cell growth factor

Indexed keywords

ANGIOGENIC FACTOR; INTERLEUKIN 17; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER STAGING; CD4+ T LYMPHOCYTE; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EARLY CANCER; FEMALE; HUMAN; MALE; MEDIATOR; MICROVASCULATURE; MULTIPLE MYELOMA; STATISTICAL SIGNIFICANCE; VASCULAR ENDOTHELIUM;

EID: 33749989367     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2006.02.012     Document Type: Article

References (26)

1. Yao Z., Painter S.L., Fanslow W.C., et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 155 (1995) 5483-5486
2. Jovanovic D.V., Di Battista J.A., Martel-Pelletier J., et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 160 (1998) 3513-3521
3. Broxmeyer H.E. Is interleukin 17, an inducible cytokine that stimulates production of other cytokines, merely a redundant player in a sea of other biomolecules?. J Exp Med 183 (1996) 2411-2415
4. Ye P., Rodriguez F.H., Kanaly S., et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 194 (2001) 519-527
5. Numasaki M., Fukushi J., Ono M., et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 101 (2003) 2620-2627
6. Takahashi H., Numasaki M., Lotze M.T., and Sasaki H. Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett 98 (2005) 189-193
7. Lauta V.M. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 97 (2003) 2440-2452
8. Alexandrakis M.G., Passam F.J., Ganotakis E., et al. Bone marrow microvascular density and angiogenic growth factors in multiple myeloma. Clin Chem Lab Med 42 (2004) 1122-1126
9. Dankbar B., Padro T., Leo R., et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95 (2000) 2630-2636
10. Alexandrakis M.G., Passam F.H., Boula A., et al. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann Hematol 82 (2003) 19-23
11. Ribatti D. The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. Br J Haematol 128 (2005) 303-309
12. Pruneri G., Ponzoni M., Ferreri A.J., et al. Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol 118 (2002) 817-820
13. Durie B.G., and Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36 (1975) 842-854
14. Taylor C.R., and Cote R.J. Immunomicroscopy; a diagnostic tool for the surgical pathologist (1994), WB Saunders Co, Philadelphia
15. Alexandrakis M.G., Passam F.H., Pappa C.A., et al. Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes. Leuk Res 29 (2005) 41-46
16. Vermeulen P.B., Gasparini G., and Fox S.B. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 38 (2002) 1564-1579
17. Numasaki M., Lotze M.T., and Sasaki H. Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett 93 (2004) 39-43
18. Vacca A., Ribatti D., Presta M., et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93 (1999) 3064-3073
19. Niemoller K., Jakob C., Heider U., et al. Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. J Cancer Res Clin Oncol 129 (2003) 234-238
20. Di Raimondo F., Azzaro M.P., Palumbo G., et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 85 (2000) 800-805
21. Choi J.H., Ahn M.J., Jang S.J., et al. Absence of clinical prognostic value of vascular endothelial growth factor and microvessel density in multiple myeloma. Int J Hematol 76 (2002) 460-464
22. Ria R., Vacca A., Russo F., et al. A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thromb Haemost 92 (2004) 1438-1445
23. Wrobel T., Mazur G., Jazwiec B., and Kuliczkowski K. Interleukin-17 in acute myeloid leukemia. J Cell Mol Med 7 (2003) 472-474
24. Sezer O., Niemoller K., Jakob C., et al. Relationship between bone marrow angigenesis and plasma cell infiltration and serum betaz-microglobulin levels in patients with multiple myeloma. Ann Hematol 80 (2001) 598-601
25. Koike M., Sekigawa I., Okada M., et al. Relationship between CD4(+)/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16. Leuk Res 26 (2002) 705-711
26. Mozaffari F., Hansson L., Kiaii S., et al. Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage. Br J Haematol 124 (2004) 315-324